Here, after 68 weeks, the semaglutide group saw an average 15.8% reduction in body weight from baseline, as opposed to the 6.4% reduction with liraglutide.26 So, while semaglutide is less clinically effective than tirzepatide, its a demonstrably excellent GLP-1 solution for weight loss
The product sold by clinics is a synthetic 15-amino-acid peptide manufactured by "solid-phase synthesis", administered under the skin, into the muscle or a joint, or intravenously, often at higher doses for weeks
Furthermore, because the drug still manipulates your metabolic baseline, the risk of rebound weight gain after stopping remains just as real." Several groups should avoid GLP-1s entirely: Those with a personal or family history of medullary thyroid carcinoma or MEN2 Anyone with an active eating disorder Anyone pregnant, breastfeeding, or planning to become pregnant within the next two months (per FDA guidance) Despite how easy it's become to get GLP-1s online via telehealth, a standard prescription model bypasses critical clinical safety guardrails
doi: 10.1089/thy.2014.0029 58 NegroRGrecoGMangieriTPezzarossaADazziDHassanH
10.1186/s11689-017-9203-z J